Stay updated on Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.

Latest updates to the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page
- ChecktodayChange DetectedA Locations section now includes North Carolina (Durham, NC) for the study, replacing the former 'North Carolina Locations' entry. The HHS Vulnerability Disclosure link was removed from the footer, and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check29 days agoChange DetectedThe Publications note was updated to indicate that PubMed auto-filled publications may not be about the study, and the revision label was updated to v3.3.2.SummaryDifference0.1%

- Check36 days agoChange DetectedThe funding/operating status notice was removed from the page.SummaryDifference0.4%

- Check50 days agoChange DetectedThe study details page appears unchanged between versions; no new content or deletions are evident in the screenshots. The overall layout and information remain the same.SummaryDifference0.5%

- Check79 days agoChange DetectedUpdated operating-status notice and version 3.2.0; removed version 3.1.0.SummaryDifference2%

- Check86 days agoChange DetectedUpdated software version from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.